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Abstract
NUCOLL43 is a novel ovarian clear cell carcinoma (O- CCC) cell line that arose 
from a primary culture of a patient’s malignant ascites. The cells grow reliably in cell 
culture with a doubling time of approx. 45 hours and form colonies at high effi-
ciency. They have a very high degree of loss of heterozygosity (LOH) affecting ap-
proximately 85% of the genome, mostly copy neutral and almost identical to the 
original tumor. The cells express epithelial (pan- cytokeratin) and mesenchymal (vi-
mentin) characteristics, CA125 and p16, like the original tumor. They also express 
ARID1A but not HNF- 1β and, like the original tumor, and are negative for p53 ex-
pression, with no evidence of p53 function. NUCOLL43 cells express all other DNA 
damage response proteins investigated and have functional homologous recombina-
tion DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and 
MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP- BEZ235. 
The NUCOLL43 cell line represents a distinct subtype of O- CCC that is p53 and 
HNF- 1β null but expresses ARID1A. Its high degree of similarity with the original 
tumor genomically and proteomically, as well as the high level of LOH, make this an 
interesting cell line for O- CCC research. It has been deposited with Ximbio.
K E Y W O R D S
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1 |  INTRODUCTION
Ovarian cancer is the 7th most common cancer in women, 
with half the cases being in women under 65. Each year, there 
are around 240 000 newly diagnosed cases and >150 000 
women die of ovarian cancer worldwide.1 Despite advances 
in surgery and chemotherapy, ovarian cancer has a relatively 
poor 5- year survival rate of approximately 45% in developed 
countries. This is largely due to late stage at diagnosis, as a 
consequence of the lack of specific symptoms and the ab-
sence of reliable screening tests.2
There are a number of different histological subtypes of 
ovarian cancer, each with different etiologies, clinical presen-
tations, and mortality rates, and each associated with distinct 
clusters of mutations.3 Despite the wide variability between 
these histological subtypes, they are currently all treated the 
same with cytoreductive surgery and platinum/taxane- based 
chemotherapy.4 Nearly all of the most common subtype, high- 
grade serous ovarian cancer (HGSC) has TP53 mutations, 
and just over half are associated with BRCA mutations or 
other defects in the BRCA- associated homologous recombi-
nation DNA repair (HRR) pathway. These mutations under-
lie their sensitivity to platinum therapy, with initial response 
rates of 70%, and the recently introduced PARP inhibitors.5
Estimates of the frequency of clear cell carcinoma of the 
ovary (O- CCC) vary substantially in the literature from 4%- 
5% up to 26%.6 Variation may reflect differences in ethnicity 
and demographics of the populations sampled, sample size, 
and trends to increased diagnosis with time,7 which may also 
reflect trends in pathological diagnoses. The cell of origin 
for O- CCC is believed to be endometrial, and endometriosis 
is a known risk factor for O- CCC.3 Overexpression of TP53 
(in its mutated inactive form) is seen in only 10%- 20% of O- 
CCC cases, in contrast to the high incidence seen in HGSC.8 
Generally, O- CCCs respond poorly to chemotherapy with 
response rates of 15%- 45%, with the higher response rates 
possibly attributable to misdiagnosis of HGSC as O- CCC.6 
The high rates of resistance in O- CCC highlight the need 
for further research to better understand the biology of this 
subset of ovarian cancer as well as therapies targeting their 
unique biology.9
Cell lines are the most commonly used model to study 
cancer in vitro. The numerous HGSC cell lines available were 
key in identifying BRCA/HRR pathway defects as major de-
terminants of sensitivity to platinum- based and PARP inhibi-
tor chemotherapy for this subset of ovarian cancer. However, 
there are far fewer cell lines available that model the other 
subtypes of ovarian cancer. For O- CCC, 27 cell lines have 
been described (Table S1), but most have not been exten-
sively characterized and only 14 have been deposited in cell 
banks. Furthermore, recent research has highlighted cases 
of subtype misclassification of existing ovarian cancer cell 
lines.10,11
The aim of this study was to characterize a novel cell line, 
designated NUCOLL43, which was derived from the ascitic 
fluid of a patient with clear cell adenocarcinoma of gyneco-
logical origin. NUCOLL43 cells grow well in culture with a 
consistent growth rate and stable phenotype. It is represen-
tative of its tumor of origin based on the pan- genomic and 
phenotypic similarity to the original tumor. NUCOLL43 cells 
are resistant to cisplatin and the PARP inhibitor rucaparib, 
but sensitive to paclitaxel, camptothecin, and to NVP- BEZ 
235. Interestingly, the cell line shows complete loss of TP53 
function and expressed protein despite no evidence of chro-
mosome 17p deletion. It exhibits a high level of copy neutral 
loss of heterozygosity.
2 |  MATERIALS AND METHODS
2.1 | Chemicals and reagents
All chemicals and reagents were obtained from Sigma (Poole, 
UK) unless otherwise stated. Camptothecin, paclitaxel, ru-
caparib (a gift from Pfizer Global R&D), VE- 821, NVP 
BEZ235 (Selleckchem), Nutlin- 3 (NewChem, Newcastle, 
UK) and RG7388 (kindly provided by Newcastle Anticancer 
Drug Development Initiative) were dissolved in dry dimethyl 
sulfoxide (DMSO) at concentrations of 1- 10 mmol/L and 
stored as aliquots at −20°C. Cisplatin was dissolved in PBS 
at 1 mmol/L and stored in aliquots at −20°C.
2.2 | Cell line establishment
The cell line described in this study, NUCOLL43, was es-
tablished from the ascitic fluid of a 57- year- old white British 
patient who presented with nonspecific symptoms of ab-
dominal bloating and distension. Subsequent investigations 
demonstrated marginally elevated serum cancer antigen 125 
(CA125) of 110 U/mL, and CT imaging showed ovarian 
masses with disseminated intra- abdominal metastases con-
sistent with advanced stage ovarian cancer (FIGO stage 3C). 
She underwent a diagnostic laparotomy to assess for cytore-
ductive surgery; however, complete cytoreduction was not 
possible due to the extensive nature of her disease. Following 
drainage of ascites, a biopsy was taken, which confirmed 
CCC of gynecological origin. The patient unfortunately de-
teriorated with progressive disease, was not fit enough to un-
dergo chemotherapy and died 6 weeks later. Ethical approval 
and written consent were obtained for the collection of clini-
cal material and patient data (REC 12/NW/0202, REC 12/
NE/0395). The aspirated ascites collected from the patient 
were cultured ex vivo as previously described.4 Following 
a period of apparent senescence at around 5 weeks, colonies 
of cells began to appear approximately 2 weeks later (Figure 
S1). From this point, the cells were cultured in RPMI- 1640 
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medium supplemented with 20% fetal bovine serum (FBS) 
(Gibco) and grown at 37°C in a 5% CO₂ humidified atmos-
phere. For all experiments, the cells used were in their expo-
nential growth phase.
2.3 | Pathology and immunohistochemistry
A portion of the tumor was removed during surgery and 
fixed in 10% buffered formalin. The formalin fixed paraffin 
embedded (FFPE) tissue was cut into four micron thick sec-
tions and taken on TOMO® Adhesive Microscope Slides. 
Immunohistochemical staining was performed using the 
streptavidin- avidin- biotin immunoperoxidase method. All 
staining procedures were performed using the fully automated 
and fully integrated Ventana BenchMark ULTRA immuno-
histochemistry platform (© 2013 Ventana Medical Systems, 
Inc.). All antibodies used were supplied as ready to use, predi-
luted kits by Ventana Medical Systems (including cytokeratin, 
vimentin, p16, p53 clone DO- 7, Estrogen receptor clone SP- 1, 
CA125 OC125, PAX 8 MRQ- 50, Napsin A clone MRQ60). 
Immunostained sections were analyzed with Olympus System 
Microscope BX43 and Leica DM2500 microscopes.
2.4 | Genetic analysis
Karyotyping and SNP array analysis was carried out by the 
Northern Genetics Service. For SNP array analysis, DNA 
was extracted using a Qiagen QIAamp DNA Kit and sym-
phony robot (NUCOLL43 cells and whole blood) or EZ1 
robot (tumor) according to the manufacturer’s instructions. 
DNAs were hybridized to whole genome Infinium CytoSNP- 
850K BeadChip arrays (Illumina, San Diego, CA, USA) and 
results were analyzed using BlueFuse Multi v4.4 software 
(Illumina).
2.5 | Short tandem repeat (STR) analysis
STR profiling was performed by NewGene Limited follow-
ing extraction of DNA from frozen cell pellets alongside ap-
propriate positive and negative controls. Eight short tandem 
repeat (STR) loci, plus Amelogenin, were amplified using 
the GenePrint® 10 System, supplied by Promega (Madison, 
WI, USA). The reaction products were processed using an 
Applied Biosystems® 3130× l Genetic Analyzer and the re-
sulting data interpreted using GeneMarker® v2.6.0 software 
(SoftGenetics LLC, State College, PA, USA).
2.6 | Western blot analysis
For analysis of p53 function, whole cell lysates were prepared 
from exponentially growing cells in lysis buffer (62.5 mmol/L 
Tris- HCl pH 6.8, 2% w/v SDS), 10% v/v Glycerol) and then 
sonicated. For all other proteins, exponentially growing cells 
were lysed with RIPA buffer with 1:100 protease inhibitor 
cocktail (Thermo Fisher Scientific) or Phosphosafe extrac-
tion reagent (Merck) following the manufacturer’s protocol. 
The protein content of all lysates was determined by Pierce 
BCA assays (Thermo Fisher Scientific, Waltham, MA, USA, 
Waltham, MA, USA) according to the manufacturer’s pro-
tocol. For measurement of DNA damage response (DDR), 
proteins samples were diluted in XT sample buffer (Bio- Rad, 
Hemel Hempstead, UK) and XT reducing agent (Bio- Rad) 
and 30 μg protein was loaded to each lane of a 3- 8% Criterion 
XT Tris- acetate gel (Bio- Rad) for electrophoresis. For analy-
sis of p53 function, Novex® 4- 20% Tris- glycine 12- well 
polyacrylamide gradient gels (Invitrogen, UK) were used. 
For all other proteins samples, diluted in 2x Laemmli buffer 
(Bio- Rad) and deionized water, were denatured by heating 
to 95°C for 5 minutes. 20- 25 μg of protein was loaded per 
lane into a 4- 20% Criterion TGX polyacrylamide gel (Bio- 
Rad) for electrophoresis. The separated proteins were trans-
ferred to nitrocellulose Hybond™ C membranes (Amersham, 
Buckinghamshire, UK). Membranes were blocked with 5% 
milk (w/v) or 5% BSA (w/v) (for DDR proteins) in TBST, 
before incubation with primary antibodies in the same 
buffer: mouse anti- MDM2 (1:300 Merck Millipore #: OP46- 
100UG), mouse anti- p21WAF1 1:100 (#: OP64, Calbiochem), 
mouse anti- p53 (1:500 Leica Microsystems Ltd. #: NCL- L- 
p53- DO7), rabbit anti- HNF- 1β (1:400, Sigma #: HPA002083), 
mouse anti- p16 (1:1000, Abcam #: DCS50.1), mouse anti- 
ER- α (1:200, Santa Cruz #: D- 12), rabbit anti- ARID1A 
(1:1000, Cell Signaling #: 12354), rabbit anti- ATM (1:500, 
Cell Signaling #: 2873S), goat anti- ATR (1:500, Santa Cruz 
#: 1887), rabbit anti- BRCA1 (1:500, Abcam #: 47573), rab-
bit anti- DNA- PKcs (1:500, Santa Cruz #: 9051), mouse anti-
 Ku70 (1:500, Abcam #: Ab80592), rabbit anti- Ku80 (1:500, 
Abcam #: Ab3114), PARP1 (1:500, Biovision #: 3001- 100), 
rabbit anti- RAD51 (1:100, Santa Cruz #: 8349), rabbit anti- 
XRCC1 (1:500, Santa Cruz #: 11429), mouse antiactin 
(1:1000, Sigma- Aldrich #: A4700), mouse anti- α- tubulin 
(1:20 000, Sigma #: T6074) and rabbit antivinculin (1:1000, 
Cell Signaling #: 13901). The membranes were then incu-
bated with HRP- conjugated secondary anti- mouse (Dako #: 
P0448), anti- rabbit (Dako #: P0448) or anti- goat (Santa Cruz 
#:2020) IgG antibodies were used at 1:2000. Clarity Western 
enhanced chemoluminescence substrate (Bio- Rad) was used 
to visualize the bands following the manufacturer’s protocol, 
and luminescence measured using G- box gel documentation 
system (Syngene). For analysis of p53 function, X- ray film 
(Fujifilm) was used to visualize the proteins.
2.7 | Immunofluorescence microscopy
Cells were seeded onto sterile coverslips and allowed to 
adhere and grow to 80% confluence prior to fixation with 
ice- cold methanol. Coverslips were washed with potassium 
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chloride (KCl) buffer (120 mmol/L KCl, 20 mmol/L NaCl, 
10 mmol/L Tris- HCl, 1 mmol/L EDTA plus 0.2% Triton X- 
100), blocked with 2% bovine serum albumin (BSA) diluted in 
KCl buffer, and incubated overnight at 4°C with primary an-
tibodies: mouse anti- pan- cytokeratin (1:300, Abcam #: PCK- 
26), rabbit antivimentin (1:250, Abcam #: EPR3776), mouse 
anti- P16 (1:500, Abcam #: DCS 50.1) or rabbit anti- CA125 
(1:500, Epitomics #: EPR1020(20). After washing with KCl 
buffer, coverslips were incubated with corresponding fluo-
rescently labeled secondary antibodies (Alexa Fluor 488 goat 
anti- rabbit, Alexa Fluor 546 goat anti- mouse (Invitrogen Life 
Technologies, Carlsbad, CA, USA)) diluted 1:1000 in 2% 
BSA (w/v) KCl buffer. After washing with KCl, the cover-
slips were mounted onto slides using VectaShield with DAPI 
(Vector Laboratories, Peterborough, UK) and viewed imme-
diately using a Leica DMR fluorescence microscope.
2.8 | Analysis of p53 function
The function of p53 was determined by measuring its in-
duction and stabilization following 6 hours exposure to 
0.5 μmol/L of the MDM2 inhibitor RG7388 (Idasanutlin) 
and consequent induction of MDM2 and p21 protein ex-
pression by Western blot as described above. The sensitiv-
ity of NUCOLL- 43 to the MDM2 inhibitors, Nutlin- 3a and 
RG7338 was determined as previously described.12
2.9 | Homologous recombination DNA 
repair (HRR) assay
The HRR status of the cells was assessed as previously de-
scribed.13 Briefly, cells were seeded onto glass coverslips 
and untreated or irradiated (2 Gy) and treated with rucaparib 
(10 μmol/L) for 24 hours to collapse replication forks then 
fixed in ice- cold methanol. Coverslips were blocked with KCl 
buffer containing 2% BSA (w/v), 10% skimmed milk pow-
der (w/v) and 10% goats serum (v/v) incubated overnight at 
4°C with anti- RAD51 antibody (1:500, Abcam #: ab133534) 
then anti- phospho- Histone H2A.X (Ser139) (1:1000 Merck 
#: JBW301) for 1 hour. Following incubation with Alexa 
Fluor secondary antibodies, mounting and microscopy, as 
above, the number of γH2AX and RAD51 foci/nucleus were 
counted using ImageJ software with the PZFociEZ macro 
(www.pzfociez.com). Cells were classified HRR competent 
if there was a ≥2- fold increase in RAD51 foci after DNA 
damage, confirmed by a ≥2- fold increase in γH2AX.
2.10 | Proliferation assay
Cell proliferation was assessed by measurement of protein 
content of the population by sulforhodamine B (SRB) assay 
as previously described.14 Briefly, cells were seeded at densi-
ties of between 50 and 5000 cells/well and fixed sequentially 
over a 10- day period. They were stained with 0.4% SRB and 
cell density estimated at 570 nm using a 96- well plate spec-
trophotometer (SpectraMax 250 Molecular Devices). Cell 
doubling times were calculated for cells undergoing expo-
nential growth using GraphPad Prism software (San Diego, 
CA, USA).
2.11 | Cytotoxicity assays
Colony formation assays were used to determine the cytotoxic 
effect of various drugs on the cells, as previously described.15 
Briefly, cells were seeded at densities of 50- 10 000 cells per 
well in six well plates. After 24 hours, the cells were incu-
bated with varying concentrations of a chemotherapeutic agent 
(camptothecin 0- 100 nmol/L, rucaparib 0- 100 μmol/L, pacli-
taxel 0- 100 nmol/L, cisplatin 0- 10 μmol/L (in the presence and 
absence of 1 μmol/L VE- 821), NVP- BEZ235 0- 300 nmol/L) 
for 24 hours with a final DMSO concentration of 0.5%, before 
being returned to drug- free media. For rucaparib radiopotentia-
tion studies, cells were seeded as above and irradiated (0- 8 Gy) 
in the presence and absence of 1 μmol/L rucaparib and returned 
to drug- free medium 24 hours later. After 7- day incubation, 
cells were fixed with Carnoy’s fixative (methanol: acetic acid, 
3:1 v/v) and stained with 0.4% crystal violet. Colonies were 
counted and cell survival determined by reference to the num-
ber of cells seeded and normalized to survival of vehicle alone 
(0.5% DMSO) or rucaparib or VE- 821 alone treated control 
cells. LC50 (concentration causing 50% cell death) values were 
determined by fitting a point- to- point curve using GraphPad 
Prism, (San Diego, CA, USA) version 6.
3 |  RESULTS
3.1 | Establishment in culture and 
morphology of the cell line
The morphology of the original tumor is shown in Figure 1A 
(HE X50), where clear cells are visible, indicative of O- CCC. 
The ascites were seeded in tissue culture flasks in 50% as-
citic fluid, 50% RPMI + 20% FBS. After 15 days, the me-
dium was replaced with fresh RPMI + 20% FBS at which 
stage they had typical primary epithelial culture morphology 
(Figure 1B). They underwent their first passage on day 23, 
and their epithelial nature was confirmed by pan- cytokeratin 
staining, with a second passage 10 days later. Initially, the 
cells appeared to senesce but approximately 8 days later 
colonies began to appear (Figure S1) and the cells were suc-
cessfully passaged repeatedly over several months. They 
exhibited the typical morphology of epithelial cell cultures 
(confirmed by pan- cytokeratin staining at passage 1, 7 and 
34 Figures S1 and 3) with multiple prominent nucleoli and 
grew to confluent monolayers with a cobblestone appearance 
(Figure 1C,D).
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F I G U R E  1  Morphology of the original tumor and NUCOLL43 and growth characteristics. H&E (x400) staining of the original tumor 
showing clear cells and hobnail cells (white arrow and black arrow, respectively: (A) and phase- contrast microscopy (x400) of NUCOLL43 cells in 
primary culture (B) and at passages 3 (C) and 32 (D). Cells have epithelial morphology with prominent nucleoli and grow as confluent monolayers 
with a modest change of morphology from primary culture that is then maintained over 30 passages. Cells grew exponentially with time as 
determined by SRB staining until they reached confluence (Absorbance ≈ 2) (E)
Original tumor histology Primary culture Passage 3 Passage 32
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F I G U R E  2  Results of SNP array analysis of NUCOLL43 (upper panels) and tumor (lower panels). The upper chart in each case represents 
the LogR intensity ratio (copy number), and lower chart represents the B allele frequency (zygosity). The Log R intensity ratios are broadly similar 
in NUCOLL43 and in tumor. The B allele frequency plots are also similar after subtracting the effect of presumed contaminating normal cells in the 
tumor
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The proliferation of NUCOLL43 was determined by 
SRB assay. The doubling times of cells seeded at differ-
ent densities varied from 33 to 52 hours (Figure 1E) and 
the mean doubling time of the cells at passages 13 and 
35 was 45 and 42 hours, respectively, with no significant 
difference between the two passages. STR profiling on 
NUCOLL43 was undertaken at passage 22 and 35 with 
identical results each time (TH01: 8, TPOX: 11, vWA: 16, 
CSF1PO: 13, D16S539: 10, 12, D7S820: 11, 13, D13S317: 
11, D5S818: 13 and Amelogenin: X) and without a com-
plex electropherogram, indicating the cell line was not a 
mixture and was stable. NUCOLL43 was able to form col-
onies with high efficiency (approximately 50% plating ef-
ficiency) within 2 weeks.
3.2 | Pan- genomic and Chromosomal 
analysis of NUCOLL43 and the original tumor
Single nucleotide polymorphism (SNP) array analysis of 
DNA extracted from NUCOLL43 cells revealed a near- 
diploid genome with several segmental chromosome abnor-
malities (Figure 2). Along with deletion of most of the long 
arm of chromosome 11 (11q), segmental gains were evident 
for most of the long of arm of chromosome 3 (3q), the short 
arm of chromosome 5 (5p) and 7 (7p), and a segment from 
distal chromosome 13 (13q).
A very high degree of loss of heterozygosity (LOH) was 
evident, affecting approximately 85% of the genome. Relative 
losses of whole chromosomes (monosomies) accounted for 
25% of this LOH, while 75% corresponds to chromosomal 
regions present in at least two copies, that is, copy- neutral 
LOH I uniparental disomy (UPD). Only 15% of the genome 
had retained allelic heterozygosity.
Chromosome analysis identified a hypodiploid/diploid 
karyotype, with chromosome counts ranging from 35 to 47. 
An unusually high degree of cell- to- cell karyotypic hetero-
geneity was recorded, suggesting a derangement of the mi-
totic segregation process (Figure S2). Structurally abnormal 
marker chromosomes were present that appear to correspond 
to the segments of 3q gain, 7p gain and 11q loss.
An almost identical SNP array profile was observed for 
the original tumor, with copy number and zygosity pattern 
for chromosomes 1, 3, 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 
20, 21, 22 and X being identical with NUCOLL43, taking 
into account non- neoplastic cells in the tumor sample. The 
segmental imbalances seen on chromosomes 11 and 13 in 
NUCOLL43 were also present in the tumor. Gains of 5p and 
7p were clearly evident in the NUCOLL43 genome: these 
were much less striking in the primary tumor, suggesting that 
they were present in only a minority of tumor cells. Analysis 
of DNA from whole blood from the patient showed no ge-
netic abnormalities.
F I G U R E  3  Comparison of protein expression in the original tumor and NUCOLL43 (early and late passage). Both tumor and NUCOLL43 
expressed both pan- cytokeratin and vimentin, indicative of epithelial and mesenchymal characteristics as well as CA125 and p16. Upper panel: pan- 
cytokeratin staining (x20); tumor cells show positive cytoplasmic staining. Vimentin staining (x20); tumor cells show patchy positivity, with the 
stroma surrounding showing strong positive staining. Lower panels: Both passages of NUCOLL43 highly express cytokeratin and vimentin, nuclei 
counterstained in blue with DAPI. Upper panel: The tumor cells stain positive for CA125 (x20) with clear localization to the cell membrane. Lower 
panels: CA125 is highly expressed in NUCOLL43 at P7, but low expression seen at P34. Upper panel: The tumor cells are highly positive for P16 
(x20) throughout the cell rather than distinctly cytoplasmic or nuclear. Lower panels: Both passages express p16; at P7, the staining is throughout 
the cell, and at P34, it is localized to the cytoplasm. In NUCOLL43, p16 expression was confirmed by Western blot at both passages
Pan-cytokeran Vimenn CA125 p16
NUCOLL P7
Tumour
NUCOLL P34
P16
Tubulin
P7     P34
   | 7FRANKLIN et AL.
3.3 | Proteomics of 
NUCOLL43 and the original tumor
Because of the striking genomic similarity between 
NUCOLL43 and the original tumor from which it was de-
rived we investigated the phenotypic similarity in terms of ex-
pressed proteins. The tumor was positive for pan- cytokeratin 
(an epithelial marker), p16 and CA125 (a marker of ovar-
ian cancer) with patchy/focal positive staining for vimentin 
(a mesenchymal marker) (Figure 3); and negative (null) for 
p53 (Figure S4) and estrogen receptor (ER) (not shown). 
Immunofluorescence (IF) analysis showed good concordance 
with the original tumor with NUCOLL43 positive for vimen-
tin and pan- cytokeratin at early and late passage. CA125, was 
expressed in both the tumor and NUCOLL43, but appeared 
to be weaker at the later passage. P16 was expressed at both 
passages of NUCOLL43, again correlating with the origi-
nal histology; however, the pattern of staining differed be-
tween the two passages with detection seen throughout the 
cytoplasm and nucleus at P7, in comparison with the clear 
cytoplasmic staining seen at P34 cells. In addition to the 
antigens described here, the original tumor was positive for 
CKC, CK7 and CK 5/6, negative for GATA3, CDX2, ERα, 
CK20,p63, AFP, CA19.9, TTF1 and PAX 8 and with patchy/
focal staining for calretinin, CD10, RCC, BerEP4 and WT- 1 
(data not shown).
ARID1A and HNF- 1β have been proposed as novel O- 
CCC biomarkers. NUCOLL cells were negative for HNF- 1β 
(Figure 4A) as no band of the correct molecular weight 
was seen in NUCOLL43 cells or the negative control cells 
F I G U R E  4  Expression of HNF1β, ARID1A and DNA damage response (DDR) protein expression and activity Early and late passage 
NUCOLL43 cells were negative for HNF1β protein expression (A). The antibody detected a strong band at 75 kDa that was revealed as being 
nonspecific by comparison with a positive control (IGROV1) and negative control (OVCAR3). Only in the known positive IGROV1 cells was 
a band of the correct molecular weight (~61 kDa) observed. The loading control was vinculin (A). Early and late passage NUCOLL43 cells 
expressed ARID1A by comparison with a negative control (IGROV1) and positive control (OVCAR3) cells; the loading control was vinculin (B). 
NUCOLL43 cells expressed NHEJ proteins DNA- PKcs, Ku70 and Ku80, BER proteins PARP1 and XRCC1, HRR proteins BRCA1 and RAD51, 
and DNA damage sensors ATM and ATR; the loading control was α- tubulin (C). NUCOLL43 were null for p53 and its targets MDM2 and p21 
by Western blot following induction and stabilization by the MDM2 antagonist RG7388 (RG: 0.5 μmol/L 6 h) in comparison with DMSO control 
(DM) a known p53 wt cell was included as a positive control and actin was the loading control (D). NUCOLL43 (p3) have functional HRR as 
demonstrated by the formation of RAD51 foci following exposure to 10 μmol/L rucaparib, and the image shows a single nucleus stained with 
DAPI, yH2AX immunofluorescence, and RAD51 immunofluorescence. The scatter plot shows pooled data from >100 nuclei of the number of 
yH2AX and RAD51 foci following exposure to rucaparib and 2 Gy radiation vs untreated controls (E)
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(OVCAR3) but was clearly visible in the positive control 
(IGROV1 cells). OVCAR3 as well as IGROV1 cells were 
positive for HNF- 1β by immunofluorescence (Figure S3). 
Because of this nonspecific staining, we did not inves-
tigate HNF- 1β in NUCOLL43 by immunofluorescence. 
NUCOLL43 was positive for ARID1A, with OVCAR3 and 
GROV1 providing positive and negative controls (Figure 4B).
3.4 | DNA damage response 
profiling of NUCOLL43
The acquisition of genomic instability is a key event in tu-
morigenesis and frequently the result of dysregulation of the 
DNA damage response (DDR).16 To investigate the DDR 
status of NUCOLL43 cells, both the expression of key DDR 
proteins by Western blot and functional assays were per-
formed. NUCOLL43 cells expressed XRCC1 and PARP1, 
key components of DNA base- excision repair that deals with 
the most common type of DNA damage. DNA double- strand 
breaks (DSBs) are highly lethal and are repaired by nonho-
mologous end joining (NHEJ) and homologous recombina-
tion DNA repair (HRR). NUCOLL43 cells expressed the 
NHEJ proteins DNA- PKcs, Ku70 and Ku80, as well as the 
HRR proteins RAD51 and BRCA1. NUCOLL43 cells also 
expressed ATM and ATR, the major signaling kinases that 
signal DNA damage, particularly DNA double- strand breaks 
to cell cycle checkpoints and DNA repair (Figure 4C).
There was no detectable expression of the tumor suppres-
sor, p53, in the original tumor despite no evidence of chro-
mosome 17p deletion (p53 null: Figure S4A). NUCOLL43 
cells were also consistently negative for p53 by Western blot. 
The MDM2 inhibitor (RG7388) increased p53 stabilization 
and expression of its downstream targets, p21 or MDM2 in 
a known TP53- wt cell line (positive control) but failed to in-
crease p53 stabilization and the expression of p21 or MDM2 
in NUCOLL43 cells (Figure 4D). RG7388 did not induce 
p53- specific changes in gene expression either (Figure 
S4B) and neither RG7388 nor Nutlin- 3a had any impact on 
NUCOLL43 cell proliferation (Figure S4C) confirming lack 
of p53 function.
To confirm that the expression of BRCA1 and RAD51 
conferred HRR function, the ability of NUCOLL43 cells 
to form RAD51 foci in response to DNA damage was as-
sessed. Compared to the untreated controls, rucaparib with 
IR treatment caused a 10- fold increase in yH2AX foci) with 
a 60- fold increase in RAD51 foci (Figure 4E), indicating that 
NUCOLL43 has functional HRR.
3.5 | Drug sensitivity
The accumulated data indicated that NUCOLL43 cells were 
largely similar to the original tumor; therefore, we assessed 
the sensitivity of NUCOLL43 to drugs commonly used in the 
treatment of ovarian cancer. We performed colony formation 
F I G U R E  5  Sensitivity of NUCOLL43 to cytotoxic agents. Results from colony formation assays and cell survival values obtained by 
normalization of treated cells to untreated controls (A). Error bars show the standard error of the mean (SEM). Data are representative of three 
independent experiments. The effect of NVP- BEZ235 on PI3K and mTOR activity was determined by Western blot measuring AKT and 4E- 
BP1 phosphorylation, a single representative image is shown, and data normalized to vinculin loading control are shown for three independent 
experiments (B)
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assays, the most direct measure of cell killing (Figure 5A) to 
calculate the LC50 of NUCOLL43 in response to cisplatin (a 
DNA cross- linking agent LC50 = 1.1 μmol/L), paclitaxel (an 
antitubulin agent LC50 = 1.6 nmol/L), camptothecin (a topoi-
somerase I poison LC50 = 8 nmol/L), rucaparib (a PARP 
inhibitor LC50 = 30 μmol/L), VE- 821 (an ATR inhibitor 
LC50 = 5.4 μmol/L) and NVP- BEZ235 (a pan- PI3K inhibi-
tor LC50 = 37 nmol/L) (Figure 4). NVP- BEZ 235 inhibition 
of PI3- kinase and mTOR was determined by measuring in-
hibition of AKT and 4E- BP1 phosphorylation, respectively, 
and appeared to be more potent against mTOR than PI3K 
in NUCOLL43 cells (Figure 5B). Radiosensitization by ru-
caparib was 1.4- fold at the LC50 and sensitization of cisplatin 
by VE- 821 was 1.8- fold at the LC50.
4 |  DISCUSSION
We report here the characterization of a cell line derived 
from a culture of ascites cells from a patient with clear 
cell ovarian cancer. The cells began to proliferate without 
artificial immortalization procedures and showed remark-
able pan- genomic similarity to the original tumor with only 
trivial changes observed. However, the copy number gain 
of 7p and 5p observed in NUCOLL43 was less striking in 
the tumor than in the immortalized cells, suggesting that 
NUCOLL43 was derived by expansion of a clonal sideline 
within the tumor. Like the original tumor, NUCOLL43 ex-
pressed both epithelial (pan- cytokeratin) and mesenchymal 
(vimentin) characteristics. In the tumor, vimentin expres-
sion was focal/patchy but it was expressed throughout the 
NUCOLL43 cells, again consistent with the cells being de-
rived from a clonal sideline of the original tumor that was 
vimentin- positive and with chromosome 5q and 7p copy 
number changes. NUCOLL43 has both epithelial and mes-
enchymal properties. Cells with this phenotype are reported 
to be particularly tumorigenic due to high invasiveness and 
motility, with subpopulations of vimentin- positive cells in 
ovarian cancer ascitic fluid reported to show greater inva-
siveness in vitro.17 Both the original tumor and NUCOLL 
cells expressed p16, which is considered a tumor suppres-
sor because it inhibits the initiation of S- phase. Its up-
regulation in certain advanced cancers would seem to be 
somewhat paradoxical. However, increased p16 expression 
indicates dysregulation of the pRb pathway, and in several 
tumor types, p16 overexpression is associated with poor 
prognosis. 18
CA125 serum levels are currently used as a diagnostic in-
dicator of ovarian cancer but levels are highly variable within 
ovarian cancer, with some tumors showing no increase.19, 
20 In keeping with the CA125 expression in the original 
tumor, NUCOLL43 cells expressed CA125; however, this 
seemed to be less pronounced at passage 34 than at passage 
7. CA125 is a type I transmembrane glycoprotein, which is 
shed from the cell surface during proteolytic degradation 
21 and studies have shown that trypsin can cleave CA125 
from the cell surface.22 Recovery times for the reappearance 
of cell surface markers after trypsinization can vary from 8 
to more than 24 hours.23 The possibility exists that CA125 
levels were lower in passage 34 cells merely because of 
different recovery from trypsin digestion following routine 
passage. HNF- 1β expression and ARID1A loss have been 
suggested as a biomarker for O- CCC, although its role in 
tumor progression remains largely unknown.24 NUCOLL43 
were negative for HNF- 1β but positive for ARID1A by 
Western blot. The expression of p53 was not detected in the 
original tumor or in NUCOLL43 cells and lack of p53 func-
tion was conclusively demonstrated using MDM2 inhibitors, 
which neither induced accumulation of p53 or its transcrip-
tional targets nor caused cytotoxicity in NUCOLL43 cells. 
Mutations and/or deletions of p53 are less frequent in O- 
CCC than in HGSOC.8 In a study of 155 O- CCC, 17 showed 
some unusual morphological characteristics, in addition to 
the characteristic O- CCC pathology, and of these 60% were 
negative for p53 and HNF1β.25 NUCOLL43 therefore rep-
resents a less frequent subtype of O- CCC.
Apart from the loss of p53 NUCOLL43 cells expressed 
all the DDR proteins investigated and, for BRCA1 and 
RAD51 at least, this was associated with functional DNA 
repair. The functioning of the HRR pathway underlies 
their insensitivity to PARP inhibitor- induced cytotoxicity 
(LC50 = 30 μmol/L). In a study of a panel of human can-
cer cell lines treated in a similar manner to rucaparib, cells 
that lacked HRR function had an LC50 of substantially less 
than 10 μmol/L.26 HRR dysfunction is also a determinant 
of sensitivity to cisplatin and the HRR competence of 
NUCOLL43 cells is consistent with them not being par-
ticularly sensitive to cisplatin. In contrast, they appeared to 
be relatively sensitive to both the topoisomerase I poison, 
camptothecin, and the antitubulin agent, paclitaxel. Studies 
of other O- CCC cell lines have also observed sensitivity to 
topoisomerase 1 poisons.27–29 Promising results have been 
seen in some, but not all, clinical trials of topoisomerase I 
poisons in O- CCC30 suggesting that topoisomerase I poi-
sons may be effective in the subtype of O- CCC represented 
by NUCOLL43. It is not possible to make a direct compar-
ison in terms of LC50 values with many of those reported 
in other studies due to use of different treatment protocols 
and analysis methods. NUCOLL43 cells were slightly less 
sensitive to the ATR inhibitor VE- 821 as a single agent 
than breast cancer cells using a similar assay protocol31 
and sensitization of cisplatin by VE- 821 appeared to be 
less than has been reported for other cell lines.32 Although 
NUCOLL43 cells were not sensitive to rucaparib as a sin-
gle agent the radiopotentiation by rucaparib was about 1.8- 
fold in NUCOLL43 cells, which is higher than we have 
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observed in other cell lines using colony formation assays 
and similar exposure periods.33 Interestingly, NUCOLL43 
cells were very sensitive to NVP- BEZ235 in comparison 
with other cell lines we have investigated.34 The PIK3CA- 
AKT- mTOR pathway is emerging as a possible therapeutic 
target for O- CCC35 with a number of both PIK3CA inhib-
itors and mTOR inhibitors currently in clinical trials.36 A 
recent paper by Oishi et al37 showed that O- CCC cell lines 
are more sensitive to NVP- BEZ235 than HGSOC cell lines; 
however, the PIK3CA mutation status of the O- CCC tumor 
did not appear to impact the sensitivity of these cell lines 
to NVP- BEZ235. In our study, NVP- BEZ235 appeared to 
be a more potent mTOR than PI3K inhibitor, which may 
explain why PI3K mutation status in the Oishi et al study 
did not affect sensitivity.
However, perhaps the most interesting feature of 
NUCOLL43 is its extremely high level of UPD. High lev-
els of UPD (7.8- 99.9%, median 19%) have been noted in 
ovarian cancer associated with BRCA mutations with much 
lower levels (0- 23.2% median = 0.7%) in BRCA wild- type 
ovarian cancer.38 If UPD is an indicator of HRR defects, it is 
possible that the tumor from which NUCOLL43 cells were 
derived had an HRR defect at some stage of its evolution. 
Potentially, this function needed to be restored to ensure 
the survival and progression of the tumor, thereby leav-
ing the “genomic scar” associated with its HRR- defective 
history. The finding of high UPD in the presence of HRR 
function indicates that UPD is not a good biomarker for 
defective HRR.
We believe NUCOLL43 cells represent a subtype of O- 
CCC that shows a high level of genomic and phenotypic 
similarity with the original tumor and will be a useful tool 
for the investigation of novel therapeutic options for O- 
CCC, which are sorely needed given its poor response to 
current therapy. This cell line has now been deposited with 
Ximbio.
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NOVELTY AND IMPACT
NUCOLL43 is a new, somewhat unusual, ovarian clear cell 
carcinoma (O- CCC) cell line with an extremely high level of 
loss of heterozygosity (>80%), most of which is copy neutral. 
This and its high level of genomic and proteomic similarity 
to the original tumor make it an interesting model of O- CCC. 
Its sensitivity to drugs commonly used to treat ovarian cancer 
has been determined, and it has been deposited in a com-
mercial bank.
ORCID
Nicola J. Curtin  http://orcid.org/0000-0003-1369-1843 
REFERENCES
 1. World Cancer Research Fund International webpage. http://www.
wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovari-
an-cancer-statistics. Accessed July 30, 2018.
 2. Jacobs IJ, Menon U, Ryan A, et  al. Ovarian cancer screening 
and mortality in the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS): a randomised controlled trial. Lancet. 
2016;387:945‐956.
 3. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial 
ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 
2010;34(3):433‐443.
 4. O’Donnell RL, McCormick A, Mukhopadhyay A, et al. The use 
of ovarian cancer cells from patients undergoing surgery to gen-
erate primary cultures capable of undergoing functional analysis. 
PLoS ONE. 2014;9(3):e90604.
 5. Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 
2016;27(Suppl 1):i40‐i44.
 6. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: re-
cent advances. Hum Pathol. 2009;40:1213‐1223.
 7. Chiang YC, Chen CA, Chiang CJ, et  al. Trends in incidence 
and survival outcome of epithelial ovarian cancer: 30- year na-
tional population- based registry in Taiwan J. Gynecol Oncol. 
2013;24(4):342‐351.
 8. Ho ES, Lai CR, Hsieh YT, et al. p53 mutation is infrequent in clear 
cell carcinoma of the ovary. Gynecol Oncol. 2001;80(2):189‐193.
 9. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of 
clear cell carcinoma of the ovary: a distinct histologic type with 
poor prognosis and resistance to platinum- based chemotherapy. 
Cancer. 2000;88(11):2584‐2589.
 10. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating 
cell lines as tumour models by comparison of genomic profiles. 
Nat Commun. 2013;4:2126.
 11. Beaufort CM, Helmijr JC, Piskorz AM, et al. Ovarian cancer cell 
line panel (OCCP): clinical importance of in vitro morphological 
subtypes. PLoS ONE. 2014;9(9):e103988.
 12. Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Combination 
treatment with rucaparib (Rubraca) and MDM2 inhibitors, 
Nutlin- 3 and RG7388, has synergistic and dose reduction poten-
tial in ovarian cancer. Oncotarget. 2017;8(41):69779‐69796.
 13. Patterson MJ, Sutton RE, Forrest I, et al. Assessing the function 
of homologous recombination DNA repair in malignant pleural 
effusion (MPE) samples. Br J Cancer. 2014;111:94‐100.
   | 11FRANKLIN et AL.
 14. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for 
cytotoxicity screening. Nat Protoc. 2006;1:1112‐1116.
 15. Middleton FK, Patterson MJ, Elstob CJ, et  al. Common cancer- 
associated imbalances in the DNA damage response con-
fer sensitivity to single agent ATR inhibition. Oncotarget. 
2015;6:32396‐32409.
 16. Curtin NJ. DNA repair dysregulation, from cancer driver to ther-
apeutic target. Nature Rev Cancer. 2012;12:108‐117.
 17. Strauss R, Li ZY, Liu Y, et al. Analysis of epithelial and mesen-
chymal markers in ovarian cancer reveals phenotypic heterogene-
ity and plasticity. PLoS ONE. 2011;6:e16186.
 18. Romagosa C, Simonetti S, López-Vicente L, et  al. p16(Ink4a) 
overexpression in cancer: a tumor suppressor gene associ-
ated with senescence and high- grade tumors. Oncogene. 
2011;30(18):2087‐2097.
 19. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple 
marker bioassay utilizing HE4 and CA125 for the prediction of 
ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 
2009;112:40‐46.
 20. Theriault C, Pinard M, Comamala M, et  al. MUC16 (CA125) 
regulates epithelial ovarian cancer cell growth, tumorigenesis and 
metastasis. Gynecol Oncol. 2011;121(3):434‐443.
 21. Yamada T, Hattori K, Satomi H, Okazaki T, Mori H, Hirose Y. 
Establishment and characterization of a cell line (HCH- 1) origi-
nating from a human clear cell carcinoma of the ovary. J Ovarian 
Res. 2016;9:32.
 22. Corver WE, Cornelisse CJ, Hermans J, Fleuren GJ. Limited loss 
of nine tumor- associated surface antigenic determinants after 
tryptic cell dissociation. Cytometry. 1995;19:267‐272.
 23. Huang HL, Hsing HW, Lai TC, et al. Trypsin- induced proteome 
alteration during cell subculture in mammalian cells. J Biomed 
Sci. 2010;17:36.
 24. Köbel M, Kalloger SE, Carrick J, et  al. A limited panel of im-
munomarkers can reliably distinguish between clear cell and 
high- grade serous carcinoma of the ovary. Am J Surg Pathol. 
2009;33(1):14‐21.
 25. DeLair D, Oliva E, Köbel M, Macias A, Gilks CB, Soslow RA. 
Morphologic spectrum of immunohistochemically characterized 
clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg 
Pathol. 2011;35(1):36‐44.
 26. Drew Y, Mulligan EA, Vong W-T, et  al. Therapeutic potential 
of PARP inhibitor AG014699 in human cancer with mutated or 
methylated BRCA. JNCI. 2011;103(4):334‐346.
 27. Sato S, Itamochi H, Oumi N, et al. Establishment and characteri-
zation of a novel ovarian clear cell carcinoma cell line, TU- OC- 2, 
with loss of ARID1A expression. Hum Cell. 2016;29:181‐187.
 28. Itamochi H, Kato M, Nishimura M, et al. Establishment and char-
acterization of a novel ovarian clear cell adenocarcinoma cell 
line, TU- OC- 1, with a mutation in the PIK3CA gene. Hum Cell. 
2013;26:121‐127.
 29. Ohta I, Gorai I, Miyamoto Y, et  al. Cyclophosphamide and 
5- fluorouracil act synergistically in ovarian clear cell adenocarci-
noma cells. Cancer Lett. 2001;162:39‐48.
 30. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. 
Treatment issues in clear cell carcinoma of the ovary: a different 
entity? Oncologist. 2006;11(10):1089‐1094.
 31. Abdel-Fatah TMA, Middleton FK, Arora A, et al. Untangling the 
ATR- Chk1 network for prognostication, prediction and therapeu-
tic target validation in breast cancer. Mol Oncol. 2015;9:569‐585.
 32. Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR- 
CHK1 axis in cancer therapy. Cancers. 2017;9:41.
 33. Ali M, Kamjoo M, Thomas HD, et  al. The clinically active 
PARP inhibitor AG014699 ameliorates cardiotoxicity but 
doesn’t enhance the efficacy of doxorubicin despite improving 
tumour perfusion and radiation response. Mol Cancer Ther. 
2011;10:2320‐2329.
 34. Curtin N, Matheson E, Salehan E. Mukhopadhyay Evaluating 
the potential of kinase inhibitors to suppress DNA repair and 
sensitise ovarian cancer cells to PARP inhibitors. NCRI con-
ference abstract, 2016. http://abstracts.ncri.org.uk/abstract/
evaluating-the-potential-of-kinase-inhibitors-to-suppress-dna-re-
pair-and-sensitise-ovarian-cancer-cells-to-parp-inhibitors/. 
Accessed July 30, 2018.
 35. Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the 
ovary: molecular insights and future therapeutic perspectives. J 
Gynecol Oncol. 2016;27(3):e31.
 36. LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in 
solid tumors. J Clin Oncol. 2016;34(31):3803‐3815.
 37. Oishi T, Itamochi H, Kudoh A, et al. The PI3K/mTOR dual inhib-
itor NVP- BEZ235 reduces the growth of ovarian clear cell carci-
noma. Oncol Rep. 2014;32(2):553‐558.
 38. Walsh CS, Ogawa S, Scoles DR, et al. Genome- wide loss of het-
erozygosity and uniparental disomy in BRCA1/2- associated ovar-
ian carcinomas. Clin Cancer Res. 2008;14(23):7645‐7651.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.
How to cite this article: Franklin M, Gentles L, 
Matheson E, et al. Characterization and drug 
sensitivity of a novel human ovarian clear cell 
carcinoma cell line genomically and phenotypically 
similar to the original tumor. Cancer Med. 2018;00:1–11. 
https://doi.org/10.1002/cam4.1724
